Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Reuters NewMedia - Tuesday December 18, 2001
A spokesman said in reply to queries that a study on novel fusion inhibitor T-20 showed expected results and good tolerance in children, while T-1249 was found to work in HIV patients who had developed a resistance to other medication. Roche is developing T-20 and T-1249 with U.S. biotechnology firm Trimeris (NasdaqNM:TRMS - news). T-20 is in Phase III clinical trials and T-1249 in Phase I/II trials.
A study on approved drug Viracept found that it was efficient in initiating HIV therapies, because it triggered only limited cross resistance, allowing patients to use more alternatives in later treatment.
Viracept has been approved for treating HIV.
Roche certificates were trading up 1.75 percent at 116.50 Swiss francs at 1610 GMT in a generally weaker market. Shares in rival Novartis were flat at 56.65.
011218
RE011228
Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .